Protection against shiga toxins

Toxins

Volumn 9, Issue 2, 2017, Pages

  Kavaliauskiene, Simona ^a   Dyvelingelem, Anne Berit ^a   Skotland, Tore ^a   Sandvig, Kirsten ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Chloroquine; Fluorodeoxyglucose; Hemolytic uremic syndrome; Inhibitors; Mn2+; Shiga toxin; Stx1; Stx2

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; CHIMYL ALCOHOL; CHLOROQUINE; GLOBOTRIAOSYLCERAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MANGANESE; MITOGEN ACTIVATED PROTEIN KINASE 14; N ACETYLGALACTOSAMINE; PHOSPHOLIPASE A2; ROSUVASTATIN; SHIGA TOXIN; VEROTOXIN 1; VEROTOXIN 2; ANTIDOTE; BACTERIAL PROTEIN; CERAMIDE TRIHEXOSIDE;

ARTICLE; BIOSYNTHESIS; CELL INTERACTION; CELL PROTECTION; CELL SURVIVAL; CHEMICAL STRUCTURE; ENDOPLASMIC RETICULUM; HUMAN; IC50; INTRACELLULAR TRANSPORT; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THIN LAYER CHROMATOGRAPHY; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DYSENTERY, BACILLARY; HEMOLYTIC-UREMIC SYNDROME; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PROTEIN CONFORMATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA DYSENTERIAE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIDOTES; APOPTOSIS; BACTERIAL PROTEINS; DYSENTERY, BACILLARY; HEMOLYTIC-UREMIC SYNDROME; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN BIOSYNTHESIS; PROTEIN CONFORMATION; PROTEIN TRANSPORT; SHIGA TOXINS; SHIGA-TOXIGENIC ESCHERICHIA COLI; SHIGELLA DYSENTERIAE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIHEXOSYLCERAMIDES;

EID: 85011954026     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins9020044     Document Type: Article

References (189)

1. Bergan, J.; Dyve Lingelem, A.B.; Simm, R.; Skotland, T.; Sandvig, K. Shiga toxins. Toxicon 2012, 60, 1085–1107.
2. Scheutz, F.; Teel, L.D.; Beutin, L.; Piérard, D.; Buvens, G.; Karch, H.; Mellmann, A.; Caprioli, A.; Tozzoli, R.; Morabito, S.; et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J. Clin. Microbiol. 2012, 50, 2951–2963.
3. Tesh, V.L.; Burris, J.A.; Owens, J.W.; Gordon, V.M.; Wadolkowski, E.A.; O’Brien, A.D.; Samuel, J.E. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 1993, 61, 3392–3402.
4. Siegler, R.L.; Obrig, T.G.; Pysher, T.J.; Tesh, V.L.; Denkers, N.D.; Taylor, F.B. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr. Nephrol. 2003, 18, 92–96.
5. Karch, H.; Tarr, P.I.; Bielaszewska, M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295, 405–418.
6. Palermo, M.S.; Exeni, R.A.; Fernandez, G.C. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev. Anti Infect. Ther. 2009, 7, 697–707.
7. Agger, M.; Scheutz, F.; Villumsen, S.; Molbak, K.; Petersen, A.M. Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J. Antimicrob. Chemother. 2015, 70, 2440–2446.
8. Barton Behravesh, C.; Jones, T.F.; Vugia, D.J.; Long, C.; Marcus, R.; Smith, K.; Thomas, S.; Zansky, S.; Fullerton, K.E.; Henao, O.L.; et al. Deaths associated with bacterial pathogens transmitted commonly through food: foodborne diseases active surveillance network (FoodNet), 1996–2005. J. Infect. Dis. 2011, 204, 263–267.
9. Boisen, N.; Melton-Celsa, A.R.; Scheutz, F.; O’Brien, A.D.; Nataro, J.P. Shiga toxin 2a and Enteroaggregative Escherichia coli—a deadly combination. Gut Microbes 2015, 6, 272–278.
10. Tarr, P.I.; Gordon, C.A.; Chandler, W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365, 1073–1086.
11. Gould, L.H.; Demma, L.; Jones, T.F.; Hurd, S.; Vugia, D.J.; Smith, K.; Shiferaw, B.; Segler, S.; Palmer, A.; Zansky, S.; et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin. Infect. Dis. 2009, 49, 1480–1485.
12. Brandt, J.R.; Fouser, L.S.; Watkins, S.L.; Zelikovic, I.; Tarr, P.I.; Nazar-Stewart, V.; Avner, E.D. Escherichia coli O157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J. Pediatr. 1994, 125, 519–526.
13. Hughes, D.A.; Beattie, T.J.; Murphy, A.V. Haemolytic uraemic syndrome: 17 years’ experience in a Scottish paediatric renal unit. Scott. Med. J. 1991, 36, 9–12.
14. Taylor, C.M.; White, R.H.; Winterborn, M.H.; Rowe, B. Haemolytic-uraemic syndrome: Clinical experience of an outbreak in the West Midlands. Br. Med. J. (Clin. Res. Ed.) 1986, 292, 1513–1516.
15. Bale, J.F., Jr.; Brasher, C.; Siegler, R.L. CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis. Am. J. Dis. Child. 1980, 134, 869–872.
16. Obata, F.; Tohyama, K.; Bonev, A.D.; Kolling, G.L.; Keepers, T.R.; Gross, L.K.; Nelson, M.T.; Sato, S.; Obrig, T.G. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J. Infect. Dis. 2008, 198, 1398–1406.
17. Armstrong, G.D.; Fodor, E.; Vanmaele, R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 1991, 164, 1160–1167.
18. Trachtman, H.; Cnaan, A.; Christen, E.; Gibbs, K.; Zhao, S.; Acheson, D.W.; Weiss, R.; Kaskel, F.J.; Spitzer, A.; Hirschman, G.H. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003, 290, 1337–1344.
19. Nishikawa, K.; Matsuoka, K.; Kita, E.; Okabe, N.; Mizuguchi, M.; Hino, K.; Miyazawa, S.; Yamasaki, C.; Aoki, J.; Takashima, S.; et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 2002, 99, 7669–7674.
20. Mulvey, G.L.; Marcato, P.; Kitov, P.I.; Sadowska, J.; Bundle, D.R.; Armstrong, G.D. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis. 2003, 187, 640–649.
21. Melton-Celsa, A.R.; Carvalho, H.M.; Thuning-Roberson, C.; O’Brien, A.D. Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice. Clin. Vaccine Immunol. 2015, 22, 448–455.
22. Kimura, T.; Tani, S.; Matsumoto Yi, Y.; Takeda, T. Serum amyloid P component is the Shiga toxin 2-neutralizing factor in human blood. J. Biol. Chem. 2001, 276, 41576–41579.
23. Armstrong, G.D.; Mulvey, G.L.; Marcato, P.; Griener, T.P.; Kahan, M.C.; Tennent, G.A.; Sabin, C.A.; Chart, H.; Pepys, M.B. Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: Therapeutic implications for hemolytic-uremic syndrome. J. Infect. Dis. 2006, 193, 1120–1124.
24. Kielstein, J.T.; Beutel, G.; Fleig, S.; Steinhoff, J.; Meyer, T.N.; Hafer, C.; Kuhlmann, U.; Bramstedt, J.; Panzer, U.; Vischedyk, M.; et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol. Dial. Transplant. 2012, 27, 3807–3815.
25. Orth, D.; Khan, A.B.; Naim, A.; Grif, K.; Brockmeyer, J.; Karch, H.; Joannidis, M.; Clark, S.J.; Day, A.J.; Fidanzi, S.; et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 2009, 182, 6394–6400.
26. Melton-Celsa, A.R.; O’Brien, A.D. New therapeutic developments against Shiga toxin-producing Escherichia coli. Microbiol. Spectr. 2014, 2.
27. Stein, P.E.; Boodhoo, A.; Tyrrell, G.J.; Brunton, J.L.; Read, R.J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992, 355, 748–750.
28. Fraser, M.E.; Chernaia, M.M.; Kozlov, Y.V.; James, M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1994, 1, 59–64.
29. Jacewicz, M.; Clausen, H.; Nudelman, E.; Donohue-Rolfe, A.; Keusch, G.T. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J. Exp. Med. 1986, 163, 1391–1404.
30. Lindberg, A.A.; Brown, J.E.; Stromberg, N.; Westling-Ryd, M.; Schultz, J.E.; Karlsson, K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 1987, 262, 1779–1785.
31. Lingwood, C.A.; Law, H.; Richardson, S.; Petric, M.; Brunton, J.L.; De, G.S.; Karmali, M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 1987, 262, 8834–8839.
32. DeGrandis, S.; Law, H.; Brunton, J.; Gyles, C.; Lingwood, C.A. Globotetraosylceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 1989, 264, 12520–12525.
33. Ling, H.; Boodhoo, A.; Hazes, B.; Cummings, M.D.; Armstrong, G.D.; Brunton, J.L.; Read, R.J. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 1998, 37, 1777–1788.
34. 125 I]verotoxin. Biochim. Biophys Acta 2000, 1501, 116–124.
35. Bast, D.J.; Banerjee, L.; Clark, C.; Read, R.J.; Brunton, J.L. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit. Mol. Microbiol. 1999, 32, 953–960.
36. Marcato, P.; Mulvey, G.; Armstrong, G.D. Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt’s lymphoma B cells. Infect. Immun. 2002, 70, 1279–1286.
37. 5 complex integrity and retrograde transport of Stx in HeLa cells. Pathog. Dis. 2015, 73, ftv083.
38. Fraser, M.E.; Fujinaga, M.; Cherney, M.M.; Melton-Celsa, A.R.; Twiddy, E.M.; O’Brien, A.D.; James, M.N. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 2004, 279, 27511–27517.
39. Garred, O.; van Deurs, B.; Sandvig, K. Furin-induced cleavage and activation of Shiga toxin. J. Biol. Chem. 1995, 270, 10817–10821.
40. 1 subunit in target cells. Microbiology 2007, 153, 2700–2710.
41. Zumbrun, S.D.; Hanson, L.; Sinclair, J.F.; Freedy, J.; Melton-Celsa, A.R.; Rodriguez-Canales, J.; Hanson, J.C.; O’Brien, A.D. Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. Infect. Immun. 2010, 78, 4488–4499.
42. Lingwood, C.A.; Binnington, B.; Manis, A.; Branch, D.R. Globotriaosyl ceramide receptor function—where membrane structure and pathology intersect. FEBS Lett. 2010, 584, 1879–1886.
43. Raa, H.; Grimmer, S.; Schwudke, D.; Bergan, J.; Walchli, S.; Skotland, T.; Shevchenko, A.; Sandvig, K. Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. Traffic 2009, 10, 868–882.
44. Kiarash, A.; Boyd, B.; Lingwood, C.A. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and verotoxin 2c preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 1994, 269, 11138–11146.
45. Pellizzari, A.; Pang, H.; Lingwood, C.A. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 1992, 31, 1363–1370.
46. Sandvig, K.; Bergan, J.; Kavaliauskiene, S.; Skotland, T. Lipid requirements for entry of protein toxins into cells. Prog. Lipid Res. 2014, 54, 1–13.
47. Kavaliauskiene, S.; Nymark, C.-M.; Bergan, J.; Simm, R.; Sylvanne, T.; Simolin, H.; Ekroos, K.; Skotland, T.; Sandvig, K. Cell density-induced changes in lipid composition and intracellular trafficking. Cell. Mol. Life Sci. 2013, 71, 1097–1116.
48. Kavaliauskiene, S.; Torgersen, M.L.; Dyve Lingelem, A.B.; Klokk, T.I.; Lintonen, T.; Simolin, H.; Ekroos, K.; Skotland, T.; Sandvig, K. Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport. Oncotarget 2016, 7, 79885–79900.
49. Sandvig, K.; Ryd, M.; Garred, O.; Schweda, E.; Holm, P.K.; van Deurs, B. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J. Cell Biol. 1994, 126, 53–64.
50. Bergan, J.; Skotland, T.; Sylvänne, T.; Simolin, H.; Ekroos, K.; Sandvig, K. The ether lipid precursor hexadecylglycerol causes major changes in the lipidome of HEp-2 cells. PLoS ONE 2013, 8, e75904.
51. Hughes, A.K.; Stricklett, P.K.; Schmid, D.; Kohan, D.E. Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int. 2000, 57, 2350–2359.
52. Ramegowda, B.; Samuel, J.E.; Tesh, V.L. Interaction of Shiga toxins with human brain microvascular endothelial cells: Cytokines as sensitizing agents. J. Infect. Dis. 1999, 180, 1205–1213.
53. Zumbrun, S.D.; Melton-Celsa, A.R.; O’Brien, A.D. When a healthy diet turns deadly. Gut Microbes 2014, 5, 40–43.
54. Skotland, T.; Ekroos, K.; Kavaliauskiene, S.; Bergan, J.; Kauhanen, D.; Lintonen, T.; Sandvig, K. Determining the turnover of glycosphingolipid species by stable-isotope tracer lipidomics. J. Mol. Biol. 2016, 428, 4856–4866.
55. Mahfoud, R.; Manis, A.; Lingwood, C.A. Fatty acid-dependent globotriaosyl ceramide receptor function in detergent resistant model membranes. J. Lipid Res. 2009, 50, 1744–1755.
56. Lingwood, D.; Binnington, B.; Rog, T.; Vattulainen, I.; Grzybek, M.; Coskun, U.; Lingwood, C.A.; Simons, K. Cholesterol modulates glycolipid conformation and receptor activity. Nat. Chem. Biol. 2011, 7, 260–262.
57. Mahfoud, R.; Manis, A.; Binnington, B.; Ackerley, C.; Lingwood, C.A. A major fraction of glycosphingolipids in model and cellular cholesterol-containing membranes is undetectable by their binding proteins. J. Biol. Chem. 2010, 285, 36049–36059.
58. Boerlin, P.; McEwen, S.A.; Boerlin-Petzold, F.; Wilson, J.B.; Johnson, R.P.; Gyles, C.L. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 1999, 37, 497–503.
59. Itoh, K.; Tezuka, T.; Inoue, K.; Tada, H.; Suzuki, T. Different binding property of verotoxin-1 and verotoxin-2 against their glycolipid receptor, globotriaosylceramide. Tohoku J. Exp. Med. 2001, 195, 237–243.
60. Head, S.C.; Karmali, M.A.; Lingwood, C.A. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J. Biol. Chem. 1991, 266, 3617–3621.
61. Rutjes, N.W.; Binnington, B.A.; Smith, C.R.; Maloney, M.D.; Lingwood, C.A. Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. Kidney Int. 2002, 62, 832–845.
62. Chark, D.; Nutikka, A.; Trusevych, N.; Kuzmina, J.; Lingwood, C. Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody. Eur. J. Biochem. 2004, 271, 405–417.
63. Khan, F.; Proulx, F.; Lingwood, C.A. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. Kidney Int. 2009, 75, 1209–1216.
64. Tam, P.; Mahfoud, R.; Nutikka, A.; Khine, A.A.; Binnington, B.; Paroutis, P.; Lingwood, C. Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J. Cell. Physiol. 2008, 216, 750–763.
65. Mukhopadhyay, S.; Redler, B.; Linstedt, A.D. Shiga toxin-binding site for host cell receptor GPP130 reveals unexpected divergence in toxin-trafficking mechanisms. Mol. Biol. Cell 2013, 24, 2311–2318.
66. Selyunin, A.S.; Mukhopadhyay, S. A conserved structural motif mediates retrograde trafficking of Shiga toxin types 1 and 2. Traffic 2015, 16, 1270–1287.
67. Ergonul, Z.; Clayton, F.; Fogo, A.B.; Kohan, D.E. Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr. Nephrol. 2003, 18, 246–253.
68. Lingwood, C.A. Verotoxin-binding in human renal sections. Nephron 1994, 66, 21–28.
69. Boyd, B.; Lingwood, C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989, 51, 207–210.
70. Ohmi, K.; Kiyokawa, N.; Takeda, T.; Fujimoto, J. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem. Biophys. Res. Commun. 1998, 251, 137–141.
71. Miyamoto, Y.; Iimura, M.; Kaper, J.B.; Torres, A.G.; Kagnoff, M.F. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell. Microbiol. 2006, 8, 869–879.
72. Ren, J.; Utsunomiya, I.; Taguchi, K.; Ariga, T.; Tai, T.; Ihara, Y.; Miyatake, T. Localization of verotoxin receptors in nervous system. Brain Res. 1999, 825, 183–188.
73. k antigen) and a novel platelet glycosphingolipid. Infect. Immun. 1998, 66, 4355–4366.
74. Tao, R.V.; Sweeley, C.C.; Jamieson, G.A. Sphingolipid composition of human platelets. J. Lipid Res. 1973, 14, 16–25.
75. k UDP-galactose: Galβ1-4G1cβ1-Cer α1,4-galactosyltransferase. Molecular genetic basis of the p phenotype. J. Biol. Chem. 2000, 275, 16723–16729.
76. Mangeney, M.; Richard, Y.; Coulaud, D.; Tursz, T.; Wiels, J. CD77: An antigen of germinal center B cells entering apoptosis. Eur. J. Immunol. 1991, 21, 1131–1140.
77. Engedal, N.; Skotland, T.; Torgersen, M.L.; Sandvig, K. Shiga toxin and its use in targeted cancer therapy and imaging. Microb. Biotechnol. 2011, 4, 32–46.
78. Okuda, T.; Tokuda, N.; Numata, S.; Ito, M.; Ohta, M.; Kawamura, K.; Wiels, J.; Urano, T.; Tajima, O.; Furukawa, K.; et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 2006, 281, 10230–10235.
79. Lauvrak, S.U.; Walchli, S.; Iversen, T.G.; Slagsvold, H.H.; Torgersen, M.L.; Spilsberg, B.; Sandvig, K. Shiga toxin regulates its entry in a Syk-dependent manner. Mol. Biol. Cell 2006, 17, 1096–1109.
80. Katagiri, Y.U.; Mori, T.; Nakajima, H.; Katagiri, C.; Taguchi, T.; Takeda, T.; Kiyokawa, N.; Fujimoto, J. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J. Biol. Chem. 1999, 274, 35278–35282.
81. Mori, T.; Kiyokawa, N.; Katagiri, Y.U.; Taguchi, T.; Suzuki, T.; Sekino, T.; Sato, N.; Ohmi, K.; Nakajima, H.; Takeda, T.; et al. Globotriaosyl ceramide (CD77/Gb3) in the glycolipid-enriched membrane domain participates in B-cell receptor-mediated apoptosis by regulating lyn kinase activity in human B cells. Exp. Hematol. 2000, 28, 1260–1268.
82. Torgersen, M.L.; Walchli, S.; Grimmer, S.; Skanland, S.S.; Sandvig, K. Protein kinase Cδ is activated by Shiga toxin and regulates its transport. J. Biol. Chem. 2007, 282, 16317–16328.
83. Walchli, S.; Skanland, S.S.; Gregers, T.F.; Lauvrak, S.U.; Torgersen, M.L.; Ying, M.; Kuroda, S.; Maturana, A.; Sandvig, K. The mitogen-activated protein kinase p38 links Shiga toxin-dependent signaling and trafficking. Mol. Biol. Cell 2008, 19, 95–104.
84. Klokk, T.I.; Kavaliauskiene, S.; Sandvig, K. Cross-linking of glycosphingolipids at the plasma membrane: consequences for intracellular signaling and traffic. Cell. Mol. Life Sci. 2016, 73, 1301–1316.
85. Tcatchoff, L.; Andersson, S.; Utskarpen, A.; Klokk, T.I.; Skanland, S.S.; Pust, S.; Gerke, V.; Sandvig, K. Annexin A1 and A2: Roles in retrograde trafficking of Shiga toxin. PLoS ONE 2012, 7, e40429.
86. Takenouchi, H.; Kiyokawa, N.; Taguchi, T.; Matsui, J.; Katagiri, Y.U.; Okita, H.; Okuda, K.; Fujimoto, J. Shiga toxin binding to globotriaosyl ceramide induces intracellular signals that mediate cytoskeleton remodeling in human renal carcinoma-derived cells. J. Cell Sci. 2004, 117, 3911–3922.
87. Hehnly, H.; Longhini, K.M.; Chen, J.L.; Stamnes, M. Retrograde Shiga toxin trafficking is regulated by ARHGAP21 and Cdc42. Mol. Biol. Cell 2009, 20, 4303–4312.
88. Hehnly, H.; Sheff, D.; Stamnes, M. Shiga toxin facilitates its retrograde transport by modifying microtubule dynamics. Mol. Biol. Cell 2006, 17, 4379–4389.
89. Mallard, F.; Antony, C.; Tenza, D.; Salamero, J.; Goud, B.; Johannes, L. Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of Shiga toxin B-fragment transport. J. Cell Biol. 1998, 143, 973–990.
90. Sandvig, K.; Olsnes, S.; Brown, J.E.; Petersen, O.W.; van Deurs, B. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J. Cell Biol. 1989, 108, 1331–1343.
91. Sandvig, K.; Garred, O.; Prydz, K.; Kozlov, J.V.; Hansen, S.H.; van Deurs, B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992, 358, 510–512.
92. Donta, S.T.; Tomicic, T.K.; Donohue-Rolfe, A. Inhibition of Shiga-like toxins by brefeldin A. J. Infect. Dis. 1995, 171, 721–724.
93. Sandvig, K.; Prydz, K.; Ryd, M.; van Deurs, B. Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells. J. Cell Biol. 1991, 113, 553–562.
94. Garred, O.; Dubinina, E.; Polesskaya, A.; Olsnes, S.; Kozlov, J.; Sandvig, K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J. Biol. Chem. 1997, 272, 11414–11419.
95. Garred, O.; Dubinina, E.; Holm, P.K.; Olsnes, S.; van Deurs, B.; Kozlov, J.V.; Sandvig, K. Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp. Cell Res. 1995, 218, 39–49.
96. Johannes, L.; Romer, W. Shiga toxin—From cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8, 105–116.
97. Lee, M.S.; Koo, S.; Jeong, D.G.; Tesh, V.L. Shiga toxins as multi-functional proteins: Induction of host cellular stress responses, role in pathogenesis and therapeutic applications. Toxins (Basel) 2016, 8, 77.
98. Dyve Lingelem, A.B.; Bergan, J.; Sandvig, K. Inhibitors of intravesicular acidification protect against Shiga toxin in a pH-independent manner. Traffic 2012, 13, 443–454.
99. Kavaliauskiene, S.; Skotland, T.; Sylvanne, T.; Simolin, H.; Klokk, T.I.; Torgersen, M.L.; Lingelem, A.B.; Simm, R.; Ekroos, K.; Sandvig, K. Novel actions of 2-deoxy-d-glucose: protection against Shiga toxins and changes in cellular lipids. Biochem. J. 2015, 470, 23–37.
100. Stechmann, B.; Bai, S.K.; Gobbo, E.; Lopez, R.; Merer, G.; Pinchard, S.; Panigai, L.; Tenza, D.; Raposo, G.; Beaumelle, B.; et al. Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 2010, 141, 231–242.
101. Secher, T.; Shima, A.; Hinsinger, K.; Cintrat, J.C.; Johannes, L.; Barbier, J.; Gillet, D.; Oswald, E. Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with enterohemorrhagic Esherichia coli. Antimicrob. Agents Chemother. 2015, 59, 5010–5013.
102. Tewari, R.; Jarvela, T.; Linstedt, A.D. Manganese induces oligomerization to promote down-regulation of the intracellular trafficking receptor used by Shiga toxin. Mol. Biol. Cell 2014, 25, 3049–3058.
103. Mukhopadhyay, S.; Linstedt, A.D. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012, 335, 332–335.
104. Gaston, M.A.; Pellino, C.A.; Weiss, A.A. Failure of manganese to protect from Shiga toxin. PLoS ONE 2013, 8, e69823.
105. Sandvig, K.; Brown, J.E. Ionic requirements for entry of Shiga toxin from Shigella dysenteriae 1 into cells. Infect. Immun. 1987, 55, 298–303.
106. Silberstein, C.; Copeland, D.P.; Chiang, W.; Repetto, H.A.; Ibarra, C. A glucosylceramide synthase inhibitor prevents the cytotoxic effects of Shiga toxin-2 on human renal tubular epithelial cells. J. Epithel. Biol. Pharmacol. 2008, 1, 71–75.
107. Silberstein, C.; Lucero, M.S.; Zotta, E.; Copeland, D.P.; Lingyun, L.; Repetto, H.A.; Ibarra, C. A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of Shiga toxin 2. Pediatr. Res. 2011, 69, 390–394.
108. Amaral, M.M.; Sacerdoti, F.; Jancic, C.; Repetto, H.A.; Paton, A.W.; Paton, J.C.; Ibarra, C. Action of Shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells. PLoS ONE 2013, 8, e70431.
109. Bergan, J.; Skotland, T.; Lingelem, A.B.; Simm, R.; Spilsberg, B.; Lindback, T.; Sylvanne, T.; Simolin, H.; Ekroos, K.; Sandvig, K. The ether lipid precursor hexadecylglycerol protects against Shiga toxins. Cell. Mol. Life Sci. 2014, 71, 4285–4300.
110. Binnington, B.; Nguyen, L.; Kamani, M.; Hossain, D.; Marks, D.L.; Budani, M.; Lingwood, C.A. Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling. Glycobiology 2016, 26, 166–180.
111. Becker, G.L.; Lu, Y.; Hardes, K.; Strehlow, B.; Levesque, C.; Lindberg, I.; Sandvig, K.; Bakowsky, U.; Day, R.; Garten, W.; et al. Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J. Biol. Chem. 2012, 287, 21992–22003.
112. Hardes, K.; Becker, G.L.; Lu, Y.; Dahms, S.O.; Kohler, S.; Beyer, W.; Sandvig, K.; Yamamoto, H.; Lindberg, I.; Walz, L.; et al. Novel Furin inhibitors with potent anti-infectious activity. ChemMedChem 2015, 10, 1218–1231.
113. Meshnick, S.R.; Dobson, M.J. The history of antimalarial drugs. In Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery; Rosenthal, P.J., Ed.; Humana Press: Totowa, NJ, USA, 2001; pp. 15–25.
114. Kitchen, L.W.; Vaughn, D.W.; Skillman, D.R. Role of US military research programs in the development of US Food and Drug Administration—Approved antimalarial drugs. Clin. Infect. Dis. 2006, 43, 67–71.
115. Al-Bari, M.A. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 2015, 70, 1608–1621.
116. Pascolo, S. Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur. J. Pharmacol. 2016, 771, 139–144.
117. Keeling, D.J.; Herslof, M.; Ryberg, B.; Sjogren, S.; Solvell, L. Vacuolar H(+)-ATPases. Targets for drug discovery? Ann. N. Y. Acad. Sci. 1997, 834, 600–608.
118. Parra, K.J. Vacuolar ATPase: A model proton pump for antifungal drug discovery. In Antimicrobial Drug Discovery: Emerging Strategies; Tegos, G., Mylonakis, E., Eds.; CAB International: Accra, Ghana, 2012; pp. 89–100.
119. Moreau, D.; Kumar, P.; Wang, S.C.; Chaumet, A.; Chew, S.Y.; Chevalley, H.; Bard, F. Genome-wide RNAi screens identify genes required for Ricin and PE intoxications. Dev. Cell 2011, 21, 231–244.
120. Yu, M.; Haslam, D.B. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERDj3. Infect. Immun. 2005, 73, 2524–2532.
121. Rodriguez-Menchaca, A.A.; Navarro-Polanco, R.A.; Ferrer-Villada, T.; Rupp, J.; Sachse, F.B.; Tristani-Firouzi, M.; Sanchez-Chapula, J.A. The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc. Natl. Acad. Sci. USA 2008, 105, 1364–1368.
122. Orlik, F.; Schiffler, B.; Benz, R. Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis. Biophys J. 2005, 88, 1715–1724.
123. Bachmeyer, C.; Benz, R.; Barth, H.; Aktories, K.; Gilbert, M.; Popoff, M.R. Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes and Vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxification in vivo. FASEB J. 2001, 15, 1658–1660.
124. Browning, D.J. Pharmacology of chloroquine and hydroxychloroquine. In Hydroxychloroquine and Chloroquine Retinopathy; Springer: New York, NY, USA, 2014; pp. 35–63.
125. Molina, D.K. Postmortem hydroxychloroquine concentrations in nontoxic cases. Am. J. Forensic Med. Pathol. 2012, 33, 41–42.
126. Brown, J. Effects of 2-deoxyglucose on carbohydrate metablism: review of the literature and studies in the rat. Metabolism 1962, 11, 1098–1112.
127. Wick, A.N.; Drury, D.R.; Nakada, H.I.; Wolfe, J.B. Localization of the primary metabolic block produced by 2-deoxyglucose. J. Biol. Chem. 1957, 224, 963–969.
128. D-glucose as an antagonist of glucose in yeast fermentation. J. Frankl. Inst. 1952, 253, 354–360.
129. Sols, A.; Crane, R.K. Substrate specificity of brain hexokinase. J. Biol. Chem. 1954, 210, 581–595.
130. 31P NMR and metabolic implications. Biochimie 1992, 74, 867–873.
131. Datema, R.; Schwarz, R.T. Interference with glycosylation of glycoproteins. Inhibition of formation of lipid-linked oligosaccharides in vivo. Biochem. J. 1979, 184, 113–123.
132. Desselle, A.; Chaumette, T.; Gaugler, M.H.; Cochonneau, D.; Fleurence, J.; Dubois, N.; Hulin, P.; Aubry, J.; Birkle, S.; Paris, F. Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development. PLoS ONE 2012, 7, e45423.
133. Watowich, S.S.; Morimoto, R.I. Complex regulation of heat shock- and glucose-responsive genes in human cells. Mol. Cell. Biol. 1988, 8, 393–405.
134. Shinjo, S.; Mizotani, Y.; Tashiro, E.; Imoto, M. Comparative analysis of the expression patterns of UPR-target genes caused by UPR-inducing compounds. Biosci. Biotechnol. Biochem. 2013, 77, 729–735.
135. D-glucose as an inhibitor of globotriaosylceramide biosynthesis. FEBS J. 2009, 276, 5191–5202.
136. D-glucose in hypoxic and normoxic tumor cells. Antioxid. Redox Signal. 2007, 9, 1383–1390.
137. D-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells”. Cancer Chemother. Pharmacol. 2006, 58, 725–734.
138. Datema, R.; Schwarz, R.T.; Jankowski, A.W. Fluoroglucose-inhibition of protein glycosylation in vivo. Inhibition of mannose and glucose incorporation into lipid-linked oligosaccharides. Eur. J. Biochem. 1980, 109, 331–341.
139. 3H]mannose in yeast and chick-embryo cells. Eur. J. Biochem. 1978, 87, 55–68.
140. Hoh, C.K. Clinical use of FDG-PET. Nucl. Med. Biol. 2007, 34, 737–742.
141. Kelloff, G.J.; Hoffman, J.M.; Johnson, B.; Scher, H.I.; Siegel, B.A.; Cheng, E.Y.; Cheson, B.D.; O’Shaughnessy, J.; Guyton, K.Z.; Mankoff, D.A.; et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer. Res. 2005, 11, 2785–2808.
142. Xi, H.; Barredo, J.C.; Merchan, J.R.; Lampidis, T.J. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CAMKKβ leading to autophagy. Biochem. Pharmacol. 2013, 85, 1463–1477.
143. D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother. Pharmacol. 2011, 67, 899–910.
144. Biswas, C.; Ostrovsky, O.; Makarewich, C.A.; Wanderling, S.; Gidalevitz, T.; Argon, Y. The peptide-binding activity of GRP94 is regulated by calcium. Biochem. J. 2007, 405, 233–241.
145. Hendershot, L.M. The ER function BiP is a master regulator of ER function. Mt. Sinai J. Med. 2004, 71, 289–297.
146. D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71, 523–530.
147. Saenz, J.B.; Doggett, T.A.; Haslam, D.B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 2007, 75, 4552–4561.
148. Park, J.G.; Kahn, J.N.; Tumer, N.E.; Pang, Y.P. Chemical structure of Retro-2, a compound that protects cells against ribosome-inactivating proteins. Sci. Rep. 2012, 2, 631.
149. Noel, R.; Gupta, N.; Pons, V.; Goudet, A.; Garcia-Castillo, M.D.; Michau, A.; Martinez, J.; Buisson, D.A.; Johannes, L.; Gillet, D.; et al. N-methyldihydroquinazolinone derivatives of Retro-2 with enhanced efficacy against Shiga toxin. J. Med. Chem. 2013, 56, 3404–3413.
150. Carney, D.W.; Nelson, C.D.; Ferris, B.D.; Stevens, J.P.; Lipovsky, A.; Kazakov, T.; DiMaio, D.; Atwood, W.J.; Sello, J.K. Structural optimization of a retrograde trafficking inhibitor that protects cells from infections by human polyoma- and papillomaviruses. Bioorg. Med. Chem. 2014, 22, 4836–4847.
151. Gupta, N.; Pons, V.; Noel, R.; Buisson, D.A.; Michau, A.; Johannes, L.; Gillet, D.; Barbier, J.; Cintrat, J.C. (S)-N-Methyldihydroquinazolinones are the active enantiomers of Retro-2 derived compounds against toxins. ACS Med. Chem. Lett. 2014, 5, 94–97.
152. Frank, C.; Werber, D.; Cramer, J.P.; Askar, M.; Faber, M.; an der Heiden, M.; Bernard, H.; Fruth, A.; Prager, R.; Spode, A.; et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 2011, 365, 1771–1780.
153. Bielaszewska, M.; Mellmann, A.; Zhang, W.; Kock, R.; Fruth, A.; Bauwens, A.; Peters, G.; Karch, H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect. Dis. 2011, 11, 671–676.
154. Gupta, N.; Noel, R.; Goudet, A.; Hinsinger, K.; Michau, A.; Pons, V.; Abdelkafi, H.; Secher, T.; Shima, A.; Shtanko, O.; et al. Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chem. Biol. Interact. 2016.
155. Aschner, M.; Erikson, K.M.; Herrero Hernandez, E.; Tjalkens, R. Manganese and its role in Parkinson’s disease: from transport to neuropathology. Neuromol. Med. 2009, 11, 252–266.
156. Racette, B.A.; Aschner, M.; Guilarte, T.R.; Dydak, U.; Criswell, S.R.; Zheng, W. Pathophysiology of manganese-associated neurotoxicity. Neurotoxicology 2012, 33, 881–886.
157. Vunnam, R.R.; Radin, N.S. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. Chem. Phys. Lipids 1980, 26, 265–278.
158. Jmoudiak, M.; Futerman, A.H. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 2005, 129, 178–188.
159. Barbour, S.; Edidin, M.; Felding-Habermann, B.; Taylor-Norton, J.; Radin, N.S.; Fenderson, B.A. Glycolipid depletion using a ceramide analogue (PDMP) alters growth, adhesion, and membrane lipid organization in human A431 cells. J. Cell Physiol. 1992, 150, 610–619.
160. Arab, S.; Lingwood, C.A. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J. Cell. Physiol. 1998, 177, 646–660.
161. Sandvig, K.; Garred, O.; van Helvoort, A.; van Meer, G.; van Deurs, B. Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol. Biol. Cell 1996, 7, 1391–1404.
162. Lee, L.; Abe, A.; Shayman, J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 1999, 274, 14662–14669.
163. Basu, M.; Dastgheib, S.; Girzadas, M.A.; O’Donnell, P.H.; Westervelt, C.W.; Li, Z.; Inokuchi, J.; Basu, S. Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissues. Acta Biochim. Pol. 1998, 45, 327–342.
164. Abe, A.; Gregory, S.; Lee, L.; Killen, P.D.; Brady, R.O.; Kulkarni, A.; Shayman, J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 2000, 105, 1563–1571.
165. Poole, R.M. Eliglustat: first global approval. Drugs 2014, 74, 1829–1836.
166. Belmatoug, N.; Di Rocco, M.; Fraga, C.; Giraldo, P.; Hughes, D.; Lukina, E.; Maison-Blanche, P.; Merkel, M.; Niederau, C.; Plckinger, U.; et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur. J. Intern. Med. 2016.
167. Lukina, E.; Watman, N.; Arreguin, E.A.; Banikazemi, M.; Dragosky, M.; Iastrebner, M.; Rosenbaum, H.; Phillips, M.; Pastores, G.M.; Rosenthal, D.I.; et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010, 116, 893–899.
168. Das, A.K.; Holmes, R.D.; Wilson, G.N.; Hajra, A.K. Dietary ether lipid incorporation into tissue plasmalogens of humans and rodents. Lipids 1992, 27, 401–405.
169. Iannitti, T.; Palmieri, B. An update on the therapeutic role of alkylglycerols. Mar. Drugs 2010, 8, 2267–2300.
170. Deniau, A.L.; Mosset, P.; Pedrono, F.; Mitre, R.; Le Bot, D.; Legrand, A.B. Multiple beneficial health effects of natural alkylglycerols from shark liver oil. Mar. Drugs 2010, 8, 2175–2184.
171. Matusewicz, L.; Meissner, J.; Toporkiewicz, M.; Sikorski, A.F. The effect of statins on cancer cells—Review. Tumour Biol. 2015, 36, 4889–4904.
172. Correale, M.; Abruzzese, S.; Greco, C.A.; Concilio, M.; Di Biase, M.; Brunetti, N.D. Statins in heart failure. Curr. Vasc. Pharmacol. 2012, 69, 232.
173. Paliani, U.; Ricci, S. The role of statins in stroke. Intern. Emerg. Med. 2012, 7, 305–311.
174. US Preventive Services Task Force; Bibbins-Domingo, K.; Grossman, D.C.; Curry, S.J.; Davidson, K.W.; Epling, J.W.; Garcia, F.A.; Gillman, M.W.; Kemper, A.R.; Krist, A.H.; et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA 2016, 316, 1997–2007.
175. Oda, T.; Wu, H.C. Effect of lovastatin on the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in brefeldin A-sensitive and -resistant cell lines. Exp. Cell Res. 1994, 212, 329–337.
176. Gomes, A.Q.; Ali, B.R.; Ramalho, J.S.; Godfrey, R.F.; Barral, D.C.; Hume, A.N.; Seabra, M.C. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol. Biol. Cell 2003, 14, 1882–1899.
177. Pfeffer, S.; Aivazian, D. Targeting Rab GTPases to distinct membrane compartments. Nat. Rev. Mol. Cell Biol. 2004, 5, 886–896.
178. Holstein, S.A.; Knapp, H.R.; Clamon, G.H.; Murry, D.J.; Hohl, R.J. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother. Pharmacol. 2006, 57, 155–164.
179. Schafer, W.; Stroh, A.; Berghofer, S.; Seiler, J.; Vey, M.; Kruse, M.L.; Kern, H.F.; Klenk, H.D.; Garten, W. Two independent targeting signals in the cytoplasmic domain determine trans-Golgi network localization and endosomal trafficking of the proprotein convertase furin. EMBO J. 1995, 14, 2424–2435.
180. Plaimauer, B.; Mohr, G.; Wernhart, W.; Himmelspach, M.; Dorner, F.; Schlokat, U. ‘Shed’ furin: Mapping of the cleavage determinants and identification of its C-terminus. Biochem. J. 2001, 354, 689–695.
181. Thomas, G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 2002, 3, 753–766.
182. Seidah, N.G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 2012, 11, 367–383.
183. Couture, F.; D’Anjou, F.; Day, R. On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications. Biomol. Concepts 2011, 2, 421–438.
184. De Cicco, R.L.; Bassi, D.E.; Benavides, F.; Conti, C.J.; Klein-Szanto, A.J. Inhibition of proprotein convertases: approaches to block squamous carcinoma development and progression. Mol. Carcinog. 2007, 46, 654–659.
185. D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect. Immun. 2002, 70, 7136–7139.
186. D-arginine in vitro and in vivo. Infect. Immun. 2004, 72, 602–605.
187. Basak, A. Inhibitors of proprotein convertases. J. Mol. Med. (Berl.) 2005, 83, 844–855.
188. Shayman, J.A. The design and clinical development of inhibitors of glycosphingolipid synthesis: Will invention be the mother of necessity? Trans. Am. Clin. Climatol. Assoc. 2013, 124, 46–60.
189. Liu, Y.Y.; Hill, R.A.; Li, Y.T. Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance. Adv. Cancer Res. 2013, 117, 59–89.